anonymous
Guest
anonymous
Guest
Poster is correct, the cuts are the Rheumatology positions, Janssen veryi would think the rheumatology contract would get cut first as Tremfya has been a total bust for PSA. 95% of the volume for Tremfya comes from Derm.
disappointed with sales results.